主要文件

查看所有文档

SML2196

Zotarolimus

Name: Zotarolimus
Brand: SIGMA

≥95% (HPLC)

别名:

(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin, ABT-578

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₅₂H₇₉N₅O₁₂

化学文摘社编号:

221877-54-9

分子量:

966.21

UNSPSC Code:

51111800

NACRES:

NA.77

MDL number:

MFCD09752954

Assay:

≥95% (HPLC)

Form:

powder

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

C[C@H](CC[C@@H](C[C@H](OC)/C(C)=C/C=C/C=C/[C@H](C[C@H](C([C@H](OC)[C@@H](/C(C)=C/[C@@H](C)C1=O)O)=O)C)C)O2)[C@]2(O)C(C(N3CCCC[C@H]3C(O[C@H]([C@H](C)C[C@@H]4CC[C@H](N5N=NN=C5)[C@H](OC)C4)C1)=O)=O)=O

InChI

1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1

InChI key

CGTADGCBEXYWNE-JUKNQOCSSA-N

说明

Biochem/physiol Actions

Zotarolimus is a second generation Drug Eluting Stent (DES).

Rapamycin analog with immunosuppressant and anti-proliferative activity used in coronary stents

Zotarolimus (ABT-578) is a semi-synthetic rapamycin analog with immunosuppressant and anti-proliferative activity. It binds to the FKBP12 binding protein, which subsequently binds to the mammalian target of rapamycin (mTOR) causing cell cycle arrest in the G1 phase. Zotarolimus was designed to be used for delivery from drug-eluting coronary stents to prevent restenosis.

存储类别

11 - Combustible Solids

wgk

WGK 3

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

0000348486

0000150304

0000150303

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Comparison of angioscopic findings among second-generation drug-eluting stents.

Yuji Nishimoto et al.

Journal of cardiology, 70(3), 297-302 (2016-12-31)

First-generation drug-eluting stents (DES) have reduced short-term stent failure as compared to bare-metal stents due to the inhibition of neointima hyperplasia, but instead increased the risk of very-late stent failure. Although better outcomes have been reported for second-generation DES than

Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates

Valgimigli M, et al.

Journal of the American College of Cardiology, 65(8), 805-815 (2015)

Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients.

Fabrizio D'Ascenzo et al.

European heart journal, 38(42), 3160-3172 (2017-10-12)

The differential impact on ischaemic and bleeding events of the type of drug-eluting stent [durable polymer stents [DES] vs. biodegradable polymer stents vs. bioresorbable scaffolds (BRS)] and length of dual antiplatelet therapy (DAPT) remains to be defined. Randomized controlled trials

查看所有相关文献

全球贸易项目编号

货号	GTIN
SML2196-25MG	04061835303649
SML2196-5MG	04061835303656

主要文件

Zotarolimus

≥95% (HPLC)

选择尺寸

关于此项目

assay

form

color

solubility

storage temp.

SMILES string

InChI

InChI key

Biochem/physiol Actions

安全信息

存储类别

wgk

文件

分析证书(COA)

已有该产品？

同行评审论文

全球贸易项目编号